Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Humacyte ( (HUMA) ) has provided an update.
On October 6, 2025, Humacyte, Inc. entered into a securities purchase agreement to sell approximately $60 million worth of common stock and warrants in an oversubscribed registered direct offering. The offering, expected to close on October 8, 2025, involves the sale of 28,436,018 shares and warrants at a price of $2.11 each, with the warrants exercisable 180 days post-issuance and expiring in 2031. D. Boral Capital LLC is acting as the exclusive placement agent, and the offering is made under the company’s effective shelf registration statement filed with the SEC. This move is anticipated to bolster Humacyte’s financial position, aiding in its strategic growth and development plans.
The most recent analyst rating on (HUMA) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on Humacyte stock, see the HUMA Stock Forecast page.
Spark’s Take on HUMA Stock
According to Spark, TipRanks’ AI Analyst, HUMA is a Neutral.
Humacyte’s overall stock score reflects significant financial and technical challenges. The lack of revenue, persistent losses, and negative equity weigh heavily on the financial performance. Technical analysis indicates bearish momentum. The valuation metrics suggest the stock may be overpriced given the negative P/E ratio and absence of dividends. The earnings call offered some optimism regarding future growth due to FDA approvals and product launches, but these are long-term prospects amid current financial difficulties. Recent corporate events provide mixed signals with potential legal risks and a successful capital raise.
To see Spark’s full report on HUMA stock, click here.
More about Humacyte
Humacyte, Inc. is a commercial-stage biotechnology platform company focused on developing universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems. These products are designed to improve patient outcomes and transform medical practices. The company’s acellular tissue engineered vessel (ATEV) has received FDA approval for extremity vascular trauma and is in late-stage clinical trials for other vascular applications. Humacyte is also engaged in preclinical development for various medical applications, including coronary artery bypass grafts and pediatric heart surgery.
Average Trading Volume: 4,615,790
Technical Sentiment Signal: Sell
Current Market Cap: $393.9M
For a thorough assessment of HUMA stock, go to TipRanks’ Stock Analysis page.